Serina Therapeutics, Inc.
Serina Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing wholly owned drug candidates for neurological diseases and other indications. Its core platform, POZ, uses a synthetic poly(2-oxazoline) polymer to modify how drugs are loaded and released, with applications across small molecules, RNA-based therapeutics, and antibody-based drug conjugates.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSynthetic polymer-based formulation technology used to improve drug loading and release control.
A neurological disease program intended for advanced Parkinson’s disease.
Wholly owned preclinical and early clinical assets built on the POZ platform.
Internal discovery, preclinical testing, and clinical development activities.
Asiakkaat
Serina does not yet sell approved products; its near-term counterparties are regulators, clinical investigators, contract manufacturers, and potential development partners. If its programs advance, the end customers would be patients, physicians, and third-party payors in neurological and other therapeutic markets. The company’s commercial model is therefore centered on drug approval, clinical validation, and potential partnering rather than direct product sales today.
Future end users of approved therapies such as SER 252, especially in Parkinson’s disease and related indications.
Prescribers who would adopt the therapy if clinical data, safety, and convenience support use.
FDA and other authorities review INDs, clinical data, and marketing applications that determine whether programs can advance.
Potential collaborators or licensees that may fund, develop, or commercialize POZ-enabled candidates.
CMOs and API suppliers that produce clinical and future commercial material for the pipeline.
Strategia
Serina’s strategy is to advance POZ-enabled drug candidates through preclinical and clinical development, starting with SER 252. The company also seeks to preserve optionality through collaborations, licensing, and future commercialization partnerships while building the manufacturing, regulatory, and intellectual property foundation needed for approval. Capital raising remains central to funding development work and extending the pipeline.
Lead program progress is the main value driver for a clinical-stage biotech.
A broader pipeline can diversify scientific risk and create more partnering options.
Clinical and future commercial supply depend on reproducible processes and compliant facilities.
Development-stage biotech programs require ongoing external capital before product revenue exists.
Maantiede
Serina is headquartered in the United States and its development, regulatory, and financing activities are centered there. The company’s programs are intended for U.S. and global regulatory pathways, so its commercial footprint will depend on where approvals are obtained and where partners choose to launch products. As a clinical-stage biotech, its geographic exposure is driven more by regulatory jurisdiction and manufacturing sourcing than by current sales geography.
Riskit
Serina faces the core risks of clinical-stage biotechnology: uncertain trial outcomes, regulatory delays, and the possibility that product candidates never reach approval. Its platform and lead program also depend on intellectual property protection, manufacturing execution, and access to capital, while any approved product would still face reimbursement and commercial adoption hurdles. The company’s recent clinical hold on SER 252 illustrates how formulation or regulatory questions can delay development even when the active drug mechanism is not the issue.
- Regulatory delay or clinical holdVaikutus: KorkeaTodennäköisyys: Korkea
Drug development depends on FDA acceptance of INDs and trial plans, which can be slowed by data or formulation questions.
Kohdistuu: SER 252 and future pipeline programs
- Clinical failure or weak efficacy/safety profileVaikutus: KorkeaTodennäköisyys: Korkea
The company’s value depends on demonstrating that POZ-enabled candidates are safe and effective in humans.
Kohdistuu: Lead and follow-on programs
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
As a pre-revenue biotech, Serina must raise external capital to fund R&D and operations.
Kohdistuu: Equity issuance and private placements
- Manufacturing and supply-chain execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Clinical and future commercial supply depend on third-party manufacturing and reproducible processes.
Kohdistuu - Intellectual property and freedom-to-operate riskVaikutus: KeskitasoTodennäköisyys: Matala
The POZ platform and product candidates rely on patent protection and defense against third-party claims.
Kohdistuu: Platform technology and candidate portfolio
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical costs are expensed as incurred, so trial timing can move quarterly results materially.
Vaikutus: Affects operating loss and comparability across periods
Capital raises and warrant exercises can create non-cash gains or losses depending on instrument terms.
Vaikutus: Can distort net income/loss versus cash burn
Equity awards are common in biotech and can be a meaningful non-cash expense in R&D and G&A.
Vaikutus: Affects reported operating expenses and dilution analysis
Pre-revenue biotech companies must disclose whether available cash is sufficient to fund operations.
Vaikutus: Signals financing risk and potential future dilution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Filana Therapeutics, Inc
FLNA · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Reviva Pharmaceuticals Holdings, Inc.
RVPH · Pharmaceutical Preparations
Päivitetty: 24.9.2026